Jeevan Scientific Technology L

Runs clinical research and bioanalytical work for pharmaceutical clients from facilities in Hyderabad. The core business is Clinical Research Services, which contributed 79.3% of segment revenue at Rs 58.42 crore with EBIT of Rs 15.27 crore, covering Bioavailability/Bioequivalence (BA/BE) studies, clinical pharmacology trials, and bioanalytical work. CDSCO has approved expanding the Hyderabad BA/BE centre beds from 132 regular and 6 ICU beds to 156 regular and 8 ICU beds, and the USFDA inspected the Manikonda bioanalytical facility in July 2026 with zero 483 observations. An Information Technology Services line contributed 15.3% of segment revenue at Rs 11.25 crore but was loss-making at the EBIT level. A Profit on Sale of Investments stream added another 5.5% of segment revenue. Employee costs are the largest expense at 35.2% of revenue, followed by other operating expenses at 41.0% and depreciation at 10.8%. FY26 consolidated revenue was Rs 61.54 crore with net profit of Rs 1.03 crore.